

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. It contains the Resolutions to be voted on at a General Meeting of the Company to be held on 6 August 2008. If you are in any doubt about the contents of this document or the action you should take you should consult an independent adviser authorised under the Financial Services and Markets Act 2000 immediately.

If you have sold or otherwise transferred all of your Ordinary Shares in the Company (“the Company”), please send this document, together with the accompanying Form of Proxy, to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some of your Ordinary Shares in the Company, you should consult with the stockbroker, bank or other agent through whom the sale or transfer was effected.

SYNTOPIX GROUP PLC

(Registered in England and Wales No. 05656604)

Placing of 2,000,756 new Ordinary Shares

at 75 pence per new Ordinary Share

and

Notice of General Meeting

Your attention is drawn to the letter from the Chairman of the Company which is set out in this document and which recommends you vote in favour of the Resolutions to be proposed at the General Meeting referred to below.

The Notice of General Meeting to be held at 10.00 a.m. on 6 August 2008 at the registered office of the Company, is set out at the end of this document.

Shareholders are asked to complete and return the enclosed Form of Proxy in accordance with the instructions printed thereon as soon as possible but, in any event, so as to be received by the Company at its registered address, Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP or by fax on 0845 125 9205, marked “For the attention of Darren Bamforth”, not later than 10.00 a.m. on 4 August 2008. Completion and return of a Form of Proxy will not preclude Shareholders from attending and voting at the General Meeting should they so wish.

This document does not constitute or form part of any offer or instruction to purchase, subscribe for or sell any shares or other securities in the Company nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with any contract therefore.

CONTENTS

	<i>Page</i>
Letter from the Chairman of Syntopix Group plc	3
Definitions	8
Notice of General Meeting	10

LETTER FROM THE CHAIRMAN OF SYNTOPIX GROUP PLC



(Incorporated and registered in England and Wales, registered number 05656604)

Directors:

Dr Rodney Harry Adams (Chairman)
Dr Stephen Philip Jones (Chief Executive Officer)
Dr Elizabeth Anne Eady (Scientific Director)
Dr Jonathan Howard Cove (Research Director)
Jay Darren Bamforth (Finance Director)
Dr Gwynfor Owen Humphreys (Senior Non-executive Director)
Alan John Aubrey (Non-executive Director)
Dr Helen Margaret Shaw (Non-executive Director)

Registered Office:

Institute of Pharmaceutical
Innovation
University of Bradford
Bradford BD7 1DP

14 July 2008

To Shareholders and, for information only, to the holders of Options

Dear Shareholder

**Proposed Placing of 2,000,756 new Ordinary Shares
at a price of 75 pence per new Ordinary Share
and
Notice of General Meeting**

1. Introduction

Your Board announced today that the Company is intending to raise £1.5 million (before expenses of approximately £10,000 plus VAT) by way of a placing of 2,000,756 new Ordinary Shares at a price of 75 pence per new Ordinary Share. The net proceeds of the Placing will be used by the Group to undertake a further human use study with a new test compound which the Group expects to commence in the first quarter of 2009, as additional working capital to fund the Group's ongoing research and business development activities and in maintaining and further developing the Company's intellectual property portfolio. The Placing is conditional upon the Company obtaining approval from its Shareholders to grant the Board authority to allot the Placing Shares and to disapply statutory pre-emption rights which would otherwise apply to the allotment of the Placing Shares. The Placing is also conditional upon a minimum of £1.2 million being raised and Admission.

This document explains the background to, and reasons for, the Placing and explains why the Independent Directors consider the Placing to be in the best interests of the Company and its Shareholders as a whole and why the Independent Directors recommend that you vote in favour of the Resolutions to be proposed at the General Meeting, notice of which is set out at the end of this document.

The Board are asking Shareholders to consider carefully the proposed Placing as, in its absence, the Board is of the opinion that the Company may not have sufficient working capital for the 12 month period following the date of this document. As such, the Board believes that it is important that Shareholders vote in favour of the Resolutions at the General Meeting to ensure the continued development of the Group. If the Resolutions are not passed at the General Meeting, the Company may not be able to pay its debts as and when they fall due which, at such time, could result in either a substantial reorganisation of the Group such that the business would only be able to operate at a considerably reduced level or a cessation of the Group's business.

2. Background to and Reasons for the Placing

Since its admission to AIM in March 2006, Syntopix has continued to progress its drug development programme in dermatology and to enhance its profile amongst prospective partners. The Group has continued to work on the discovery of compounds and combinations of compounds for use in the treatment of acne and the prevention and treatment of superficial skin infections due to *Staphylococcus aureus* including MRSA. Its library of compounds now stands at 1,400 compounds and continues to grow.

In December 2007, the Group signed an exclusive evaluation agreement with a major consumer healthcare company to evaluate the Group's library of compounds for their potential usefulness in oral healthcare. In addition, the Group has just announced that it has entered into a joint development agreement with Procter & Gamble, the world's largest consumer goods product company, to investigate the use of the Group's antimicrobial technology with the objective of improving the efficacy of one of Procter & Gamble's major consumer healthcare brands.

The Group also announced in February 2008 positive results from its first Phase II proof-of-concept clinical study in subjects with acne-prone skin. The results demonstrated that the Group's product reduced the total number of acne spots to a significantly greater extent than a currently marketed cosmetic product.

There is a continuing demand for new antimicrobial products. The Directors believe that the main drivers behind this demand are the need for new cost-effective antimicrobials in the consumer health care market and the increase in antibiotic resistance. The Directors further believe that the Group can provide such cost-effective and safe antimicrobials from its library of existing compounds and combinations of compounds and is able to generate, from its research activities, further potentially promising synergistic combinations. The Group's short to medium term intention is therefore to seek to license its compounds to suitable partners in the cosmetics and/or the consumer healthcare industries.

Whilst the Company has made significant progress during the financial year to date, consistent with statements made in the Group's 2007 Annual Report and the Interim Results for the 6 months ended on 31 January 2008 published in April 2008, the Group now requires additional funding to enable its planned development programme to continue.

The Board is of the opinion that, without completion of the Placing, the working capital currently available to Syntopix is not sufficient for its requirements for the next 12 months following the date of this document.

In order to resolve this situation, the Board has considered various options to refinance the Company. These have included granting an early licence of, or entering into a strategic partnership in respect of, its existing compounds as well as considering an issue of equity in the Company to potential new and existing investors.

Due to the Company's present financial position and the stage of development of its business and compounds, the Board does not believe that the licensing of, or the entering into of a strategic partnership in respect of, any of its compounds and intellectual property would result in the Company achieving a fair value for any such compounds. The Board do not consider that any such licensing or partnership arrangements would therefore be in the best interests of the Company or Shareholders as a whole.

The Board has, in consultation with KBC, held meetings with a number of prospective new investors and with certain of the Company's major shareholders (by size), and has concluded that, in light of those discussions, current market conditions and the time constraints which the Company is under, the proposed Placing represents the best financing option currently available to the Company.

The Board decided not to make the Placing open to all the Shareholders on a pre-emptive basis as it felt that to do so would have resulted in both the Company incurring additional expense and with the fund raising being delayed without any certainty that all of the funds required would be raised. The Company also believes that it would be unlikely to obtain underwriters for a pre-emptive issue at a reasonable price.

3. Current trading and prospects

The Interim Results of the Group for the 6 months ended on 31 January 2008 reported wider first-half pre-tax losses following an increase in its research and development expenses for the period. Whilst revenue increased to £36,666 for the period from £2,500 reported a year ago, research and development costs rose to £668,883 from £490,763 previously.

Since the publications of the Interim Results, the Group has traded in line with expectations.

The Company is proposing to raise approximately £1.5 million through the issue of the Placing Shares at the Placing Price and following the Placing the Company will have cash resources of approximately £1,765,000.

4. Details of the proposed Placing

The Company is proposing to raise £1.5 million, before expenses, by way of a conditional placing of 2,000,756 new Ordinary Shares at 75 pence per new Ordinary share. The Placing Shares will represent 25.87 per cent. of the enlarged issued share capital of the Company at Admission, assuming all Placing Shares are placed. The Placing is conditional upon (i) the passing of the Resolutions; (ii) the Company raising a minimum of £1.2 million; and (iii) Admission. The Placing Shares will, when issued, rank *pari passu* in all respects with the Ordinary Shares then in issue, including the right to all dividends and other distributions declared, made or paid following Admission.

Application will be made for the Placing Shares to be admitted to AIM. It is expected that trading in the Placing Shares will commence on 12 August 2008.

Members of the Board will be subscribing for, in aggregate, 66,000 Placing Shares under the Placing. In addition, IP2IPO will be subscribing for 435,711 Placing Shares and IP Venture Fund, a fund managed by Top Technology Ventures Limited (a subsidiary of IP Group), will be subscribing for 435,711 Placing Shares.

5. Share Issuance Authorities

The Directors currently have residual authorities under section 80 and section 95 of the Act. However these would be insufficient to issue the Placing Shares. Accordingly, in order for the Company to issue the Placing Shares the Company needs to obtain approval from its Shareholders granting the Board authority to issue the Placing Shares and to disapply statutory pre-emption rights which would

otherwise apply to the issue of the Placing Shares. The Company is therefore seeking Shareholders' consent to increase the Directors' general authority to allot securities and disapply pre-emption rights pursuant to section 80 of the Act and section 95 of the Act. A summary of the Resolutions is set out in paragraph 6 below.

6. The General Meeting

In order to enable the proposed Placing to proceed, two Resolutions will be proposed at the General Meeting. The first Resolution, which will be proposed as an ordinary resolution, will seek authority for the Directors pursuant to section 80 of the Act to allot relevant securities of the Company up to an aggregate nominal amount of £200,075.60 in connection with the Placing and general authority to allot up to an aggregate nominal amount of £257,778 (which represents approximately one-third of the number of Ordinary Shares in issue immediately following completion of the Placing, assuming all Placing Shares are placed).

The second Resolution, which will be proposed as a special resolution, will seek to authorise the Directors pursuant to section 95 of the Act to allot equity securities for cash otherwise than on a pro rata basis: (i) where a pro rata offer has effectively been made, but subject to exclusions or arrangements to avoid logistical, regulatory or legal issues; (ii) up to an aggregate nominal amount of £200,075.60 in connection with the Placing; and (iii) generally up to an aggregate nominal amount of £77,335 (which represents approximately 10 per cent. of the number of Ordinary Shares in issue immediately following completion of the Placing, assuming all Placing Shares are placed).

The authorities granted pursuant to these two Resolutions will expire on the earlier of the date falling 15 months from the passing of the Resolutions and the date of the next annual general meeting of the Company after the passing of the Resolutions unless otherwise revoked.

You will find set out at the end of this document the notice of General Meeting setting out the Resolutions in full. The General Meeting is to be held at the registered office of the Company, Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, at 10.00 a.m. on 6 August 2008.

7. Action to be Taken

Enclosed with this document is a Form of Proxy for use at the General Meeting. Whether or not you intend to be present at the meeting, you are requested to complete and return the Form of Proxy to the Company at the address stated on the form by post, or by fax to 0845 125 9205, marked "For the attention of Darren Bamforth", so as to be received as soon as possible and in any event not later than 10.00 a.m. on 4 August 2008. If you complete and return the Form of Proxy, you may still attend and vote at the General Meeting should you wish to do so.

8. Recommendation

As IP2IPO are participating in the Placing and are a related party (as defined in the AIM Rules), owing to Alan Aubrey's involvement in IP Group as both Chief Executive Officer and as a shareholder, he is required to abstain from voting on the Resolutions and is not an Independent Director for the purpose of the recommendation made below.

The Independent Directors consider that the Placing is in the best interests of the Company and its Shareholders as a whole. In addition, the Independent Directors, having consulted with KBC, consider that the participation of IP2IPO and Alan Aubrey in the Placing is fair and reasonable insofar as Shareholders are concerned. Accordingly, the Independent Directors recommend that Shareholders vote in favour of the Resolutions, as they intend to do in respect of their own shareholdings, amounting in aggregate to 902,987 Ordinary Shares (representing approximately 15.75 per cent. of the current issued share capital of the Company).

Yours sincerely

A handwritten signature in black ink that reads "R. H. Adams". The signature is written in a cursive style with a horizontal line under the name.

Dr Rodney Adams
Chairman

DEFINITIONS

The following definitions apply throughout this document, unless the context requires otherwise.

“Act”	the Companies Act 1985 (as amended or superseded by the Companies Act 2006)
“Admission”	admission of the Placing Shares to trading on AIM becoming effective in accordance with Rule 6 of the AIM Rules
“AIM”	the AIM Market operated by the London Stock Exchange
“AIM Rules”	the AIM Rules for Companies
“Board” or “Directors”	the board of directors of the Company, whose names are set out on page 3 of this document
“Company” or “Syntopix”	Syntopix Group plc
“Form of Proxy”	the accompanying form of proxy for use by Shareholders in relation to the General Meeting
“General Meeting”	the general meeting of the Company convened for 10.00 a.m. on 6 August 2008 by the notice set out at the end of this document (and any adjournment thereof)
“Group”	the Company and its subsidiaries as at the date of this document
“Independent Directors”	for the purposes of any discussions in relation to the Placing, the independent directors of the Company, being each of the Directors other than Alan Aubrey
“IP2IPO”	IP2IPO Limited, a substantial shareholder in the Company
“IP Group”	IP Group plc, the parent company of IP2IPO
“KBC”	KBC Peel Hunt Limited, the nominated adviser and broker to the Company
“London Stock Exchange”	London Stock Exchange plc
“MRSA”	methicillin resistant <i>Staphylococcus aureus</i>
“Notice of General Meeting”	the notice of General Meeting, set out at the end of this document
“Options”	options to subscribe for Ordinary Shares granted by the Company
“Ordinary Shares”	ordinary shares of 10 pence each in the capital of the Company
“Placing”	the conditional placing of the Placing Shares

“Placing Price”	75 pence per Placing Share
“Placing Shares”	the 2,000,756 new Ordinary Shares to be issued pursuant to the Placing
“Resolutions”	the resolutions set out in the Notice of General Meeting
“Shareholders”	the holders of Ordinary Shares
“subsidiaries”	has the meaning ascribed thereto by the Act

SYNTOPIX GROUP PLC
(Registered Number: 05656604)

NOTICE OF GENERAL MEETING

NOTICE IS HEREBY GIVEN that a **GENERAL MEETING** of Syntopix Group plc (the “**Company**”) will be held at the registered office of the Company, Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, at 10.00 a.m. on 6 August 2008 for the purpose of considering and if thought fit passing the following resolutions which in the case of resolution 1 will be proposed as an ordinary resolution and in the case of resolution 2 will be proposed as a special resolution.

ORDINARY RESOLUTION

1. THAT, in substitution for all existing authorities, the directors be and they are hereby generally and unconditionally authorised in accordance with section 80 of the Companies Act 1985 (the “**Act**”) to exercise all the powers of the Company to allot relevant securities (within the meaning of that section) up to a maximum aggregate nominal amount of:
- (i) £200,075.60 in connection with the placing of up to 2,000,756 ordinary shares of 10 pence each in the capital of the Company (the “**Placing**”); and
 - (ii) otherwise than pursuant to paragraph (i) of this resolution, up to an aggregate nominal amount of £257,778

provided that such authority shall expire (unless previously revoked, varied or extended by the Company in general meeting) on the earlier of the date falling 15 months from the passing of this resolution and the date of the next annual general meeting of the Company after the passing of this resolution, save that the Company may before such expiry make an offer or agreement which would or might require relevant securities to be allotted after such expiry and the directors may allot relevant securities in pursuance of such offer or agreement as if the power conferred hereby had not expired and in this resolution the expression “relevant securities” and references to the allotment of relevant securities shall bear the same respective meanings as in section 80 of the Act.

SPECIAL RESOLUTION

2. THAT (subject to the passing of resolution 1 above), in substitution for all existing authorities, the directors be and are hereby empowered pursuant to section 95 of the Act to allot equity securities for cash pursuant to the authority conferred by resolution 1 above as if sub-section (1) of section 89 of the Act did not apply to any such allotment provided that this power shall be limited to:
- (i) the allotment of equity securities up to an aggregate nominal amount of £200,075.60 pursuant to the Placing;
 - (ii) the allotment of equity securities in connection with an offer of such securities by way of rights to holders of ordinary shares of 10 pence each in proportion (as nearly as may be practicable) to their respective holdings of such shares, but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or any legal or practicable problems under the laws of any territory, or the requirements of any regulatory body or stock exchange; and

- (iii) the allotment (otherwise than pursuant to paragraphs (i) and (ii) of this resolution) of equity securities up to an aggregate nominal amount of £77,335,

provided that such authority shall expire (unless previously revoked, varied or extended by the Company in general meeting) on the earlier of the date falling 15 months from the passing of this resolution and the date of the next annual general meeting of the Company after the passing of this resolution, save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the directors may allot equity securities in pursuance of such offer or agreement as if the power conferred hereby had not expired and in this resolution the expression "equity securities" and references to the allotment of equity securities shall bear the same respective meanings as in section 94 of the Act.

Dated: 14 July 2008

Registered Office:

Institute of Pharmaceutical Innovation
University of Bradford
Bradford BD7 1DP

By Order of the Board

Secretary
Jay Darren Bamforth

NOTES:

1. A member of the Company entitled to attend, speak and vote at the above meeting convened by this notice is entitled to appoint a proxy or proxies to attend, speak and vote and, on a poll, to vote instead of him or her. A member may appoint more than one proxy in relation to the meeting, provided that each proxy is appointed to exercise the rights to a different share or shares held by him or her. A proxy need not be a member of the Company.
2. To be valid the proxy must be duly executed and deposited with the Company at its registered office, or returned by fax to 0845 1259205, marked "For the attention of Darren Bamforth" not later than 10.00 a.m. on 4 August 2008.
3. Completion and return of a form of proxy will not prevent a member from attending, speaking and voting in person at the meeting if he or she so wishes.
4. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001 to be entitled to attend and vote at the meeting (and for the purposes of the determination by the Company of the number of votes they may cast), members must be entered on the Company's register of members by 10.00 a.m. on 4 August 2008 or, in the event that the meeting is adjourned, on the Register of Members of the Company as at 10.00 a.m. on the second day immediately preceding the day of the adjourned meeting, shall be entitled to attend and vote at the meeting in respect of the number of shares registered in their name at that time. Changes to entries on the Register of Members after 10.00 a.m. on 4 August 2008 or, in the event that the meeting is adjourned, after 10.00 a.m. on the second day immediately preceding the day of the adjourned meeting, shall be disregarded in determining the rights of any person to attend and vote at the meeting.
5. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of any other joint holders. For these purposes, seniority shall be determined by the order in which the names stand in the register of members in respect of the joint holding.
6. In the case of a corporation, the form of proxy must be executed under its common seal or signed

on its behalf by a duly authorised attorney or duly authorised officer of the corporation.

7. As at 7.00 a.m. on 14 July 2008 the Company's issued share capital comprised 5,732,601 ordinary shares of 10p each ("Ordinary Shares"), each Ordinary Share carries the right to one vote at a general meeting of the Company and therefore the total number of voting rights in the Company as at 7.00 a.m. on 14 July 2008 is 5,732,601.

SYNTOPIX GROUP PLC (the "Company")

FORM OF PROXY

**For use at the General Meeting of the Company to be held at the registered office of the Company,
Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP at
10.00 a.m. on 6 August 2008**

I/We.....
(Name in full in block capitals please)
of (address)

..... being
(a) member(s) of Syntopix Group plc entitled to attend and vote at General Meetings of the Company hereby
appoint the Chairman of the Meeting or (see note 1 below)

.....to act as my/our proxy and to attend
and vote for me/us on my/our behalf at the general meeting of the Company to be held at the registered
office of the Company, Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP
at 10.00 a.m. on 6 August 2008 or at any adjournment thereof, as indicated by an "X" in the appropriate box
below. This proxy form relates to the resolutions referred to below and to any other business transacted at
the meeting.

I/We instruct my/our proxy to vote as follows:

ORDINARY RESOLUTION	FOR	AGAINST	WITHHELD (see note 4 below)
1. To authorise the directors of the Company pursuant to section 80 of the Companies Act 1985 (the "Act") to allot relevant securities within the meaning of that section.			
SPECIAL RESOLUTION			
2. To authorise the directors' pursuant to section 95 of the Act to allot equity securities (as defined in section 94 of the Act) for cash disapplying the statutory pre-emption rights			

Please return this form of proxy, duly completed and signed, to the Company's registered office so as to be received not less than 48 hours before the time of the General Meeting. The address of the registered office is Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, FAO Darren Bamforth, Company Secretary. The fax number is 0845 125 9205.

Dated 2008

Signed

Notes:

1. As a member of the Company you are entitled to appoint a proxy to ensure all or any of your rights to attend, speak and vote at a general meeting of the Company. You can only appoint a proxy using the procedures set out in these notes.

2. A proxy need not be a member of the Company. If you wish to appoint a proxy other than the Chairman of the Meeting, please cross out the words "the Chairman of the Meeting or" and write the full name and address of your proxy in the space provided. The change should be initialled. You may appoint more than one proxy to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please contact Darren Bamforth, Company Secretary, Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, telephone number 0845 200 8340.
3. Please indicate with a cross in the appropriate box how you wish the proxy to vote. If you do not indicate how you wish your proxy to vote on any resolution or on any other matter (including any amendment to any resolution), the proxy will exercise his/her discretion as to how he/she votes and as to whether or not he/she abstains from voting in such manner as he/she thinks fit.
4. If you mark the box "withheld", it will mean that your proxy will abstain from voting and, accordingly, your vote will not be counted either for or against the relevant resolution.
5. Your proxy can vote for you on a poll. Your proxy can, depending on your shareholding, demand (or join in demanding) a poll on any or all of the resolutions proposed.
6. This form must be signed and dated by the shareholder or his/her attorney duly authorised in writing. In the case of a corporation this form of proxy must be executed under its common seal or under the hand of an officer or attorney duly authorised in writing.
7. A form of proxy, to be valid, must be signed and dated and must be lodged, together with the power of attorney or other authority (if any) under which it is signed, or a duly certified copy of such power or authority, with the Company at its registered office or by fax to 0845 125 9205, marked "For the attention of Darren Bamforth", not less than 48 hours before the time appointed for holding the meeting.
8. In the case of joint holders, the signature of any one of them will suffice but the names of all joint holders should be stated. The vote of the senior who tenders a vote (whether in person or by proxy) will be accepted to the exclusion of the votes of the other holders. For this purpose, seniority is determined by the order in which the names stand in the register of members in respect of the joint holding.
9. Any alteration to this form must be initialled.
10. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the time by which a person must be entered on the register of members in order to have the right to attend and vote at the general meeting is 10.00 a.m. on 4 August 2008 or, if the meeting is adjourned, such time being not more than 48 hours prior to the time fixed for the adjourned meeting. Changes to entries on the register of members after that time will be disregarded in determining the right of any person to attend or vote at the meeting.
11. Completion and return of this form of proxy does not preclude a member from subsequently attending and voting at the meeting. If you have appointed a proxy and attend the meeting in person, your proxy appointment will automatically be terminated.
12. As at 10.00a.m. on 14 July 2008, the Company's issued share capital comprised 5,732,601 ordinary shares of 10p each ("Ordinary Shares"), each Ordinary Share carries the right to one vote at a general meeting of the Company and therefore the total number of voting rights in the Company as at 10.00a.m. on 14 July 2008 is 5,732,601.